CCR1 and neoplasm: It can also interfere with M2-type tumor-associated macrophages signaling, inhibiting CCL15-CCR1-NFκB pathway activation on HNSCC and enhancing tumor susceptibility to gefitinib treatment, an EGFR inhibitor [132].